IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis

Lathika Mohanraj, Ho Seong Kim, Wei Li, Qing Cai, Ki Eun Kim, Hye Jung Shin, Yongjae Lee, Woo Jung Lee, Jung Hyun Kim, Youngman Oh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases. Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-α-induced NF-κB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-α-induced inhibition of glucose uptake. IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-κB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.

Original languageEnglish
Article numbere55084
JournalPloS one
Volume8
Issue number1
DOIs
Publication statusPublished - 2013 Jan 28

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
insulin-like growth factor binding proteins
atherosclerosis
insulin resistance
Insulin Resistance
Atherosclerosis
cytokines
Insulin
Cytokines
obesity
Endothelial cells
adipocytes
Adipocytes
endothelial cells
Anti-Inflammatory Agents
Endothelial Cells
Obesity
Proteolysis
Glucose
visceral fat

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Mohanraj, L., Kim, H. S., Li, W., Cai, Q., Kim, K. E., Shin, H. J., ... Oh, Y. (2013). IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis. PloS one, 8(1), [e55084]. https://doi.org/10.1371/journal.pone.0055084
Mohanraj, Lathika ; Kim, Ho Seong ; Li, Wei ; Cai, Qing ; Kim, Ki Eun ; Shin, Hye Jung ; Lee, Yongjae ; Lee, Woo Jung ; Kim, Jung Hyun ; Oh, Youngman. / IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis. In: PloS one. 2013 ; Vol. 8, No. 1.
@article{cf41eeb1bb3e4dd4ac2e2b0d5e5a9a0b,
title = "IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis",
abstract = "Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases. Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-α-induced NF-κB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-α-induced inhibition of glucose uptake. IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-κB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.",
author = "Lathika Mohanraj and Kim, {Ho Seong} and Wei Li and Qing Cai and Kim, {Ki Eun} and Shin, {Hye Jung} and Yongjae Lee and Lee, {Woo Jung} and Kim, {Jung Hyun} and Youngman Oh",
year = "2013",
month = "1",
day = "28",
doi = "10.1371/journal.pone.0055084",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

Mohanraj, L, Kim, HS, Li, W, Cai, Q, Kim, KE, Shin, HJ, Lee, Y, Lee, WJ, Kim, JH & Oh, Y 2013, 'IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis', PloS one, vol. 8, no. 1, e55084. https://doi.org/10.1371/journal.pone.0055084

IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis. / Mohanraj, Lathika; Kim, Ho Seong; Li, Wei; Cai, Qing; Kim, Ki Eun; Shin, Hye Jung; Lee, Yongjae; Lee, Woo Jung; Kim, Jung Hyun; Oh, Youngman.

In: PloS one, Vol. 8, No. 1, e55084, 28.01.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis

AU - Mohanraj, Lathika

AU - Kim, Ho Seong

AU - Li, Wei

AU - Cai, Qing

AU - Kim, Ki Eun

AU - Shin, Hye Jung

AU - Lee, Yongjae

AU - Lee, Woo Jung

AU - Kim, Jung Hyun

AU - Oh, Youngman

PY - 2013/1/28

Y1 - 2013/1/28

N2 - Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases. Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-α-induced NF-κB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-α-induced inhibition of glucose uptake. IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-κB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.

AB - Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases. Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-α-induced NF-κB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-α-induced inhibition of glucose uptake. IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-κB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84873857197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873857197&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0055084

DO - 10.1371/journal.pone.0055084

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e55084

ER -